Renascience Inc.
JPX: 4889.T0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Tokyo Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Toshio Miyata
- Employees
- 4
- Headquarters
- Tokyo, Japan
- IPO year
- 2021
- Market cap
- ¥16B
- Website
- https://www.renascience.co.jp
Loading 4889…
Loading profile data…Frequently asked questions about 4889
What does Renascience Inc. (4889.T) do?
Renascience Inc. engages in the development and commercialization of pharmaceuticals and medical devices in Japan. The company is developing RS5614, a PAI-1 inhibitor product candidate for use in the treatment of chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, novel coronavirus infections, and FGF23-related hypophosphat...
Where does 4889.T trade?
Renascience Inc. (4889.T) trades on the Tokyo Stock Exchange.
What sector is 4889.T in?
Renascience Inc. (4889.T) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Renascience Inc.?
Toshio Miyata is the chief executive officer of Renascience Inc. (4889.T).
Where is Renascience Inc. headquartered?
Renascience Inc. is headquartered in Japan.
Does 4889.T pay a dividend?
Renascience Inc. (4889.T) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 4889.T go public?
Renascience Inc. (4889.T) completed its initial public offering in 2021.